Biogen Inc (BIIB) Stock Analysis

Biogen Inc (BIIB) is a publicly traded company in the HEALTHCARE sector. It trades at $188.83, carries a market capitalization of $28.38B, a price-to-earnings ratio of 20.67. This page summarizes the public market data, fundamentals, and frequently asked questions for BIIB, with GNG Research's proprietary safety, quality, and valuation analysis available to members.

Sector: HEALTHCARE - DRUG MANUFACTURERS - GENERAL

Exchange: NASDAQ

Key Metrics

Market Sentiment

Biogen Inc currently has a Neutral sentiment score of 0.04.

About Biogen Inc

Biogen Inc. is a premier American biotechnology company headquartered in Cambridge, Massachusetts, specializing in the discovery and development of transformative therapies for neurological disorders. With a robust pipeline targeting critical conditions like multiple sclerosis, Alzheimer's disease, and spinal muscular atrophy, Biogen is at the forefront of addressing significant unmet medical needs. The company is dedicated to advancing therapeutic innovation and enhancing patient outcomes th...

GNG Research Analysis

GNG Research scores Biogen Inc (BIIB) on three proprietary dimensions — a Safety score, a Quality score, and a Valuation score — alongside fair value estimates and buy-price targets for 5,000+ companies. These ratings are reserved for members. Read how the scores are calculated on our methodology page, or see GNG Research plans to unlock the full rating for BIIB.

Frequently Asked Questions

Does BIIB pay dividends?

Biogen Inc (BIIB) does not currently pay a regular dividend.

What is BIIB's P/E ratio?

Biogen Inc has a price-to-earnings (P/E) ratio of 20.67.

What is BIIB's market cap?

Biogen Inc (BIIB) has a market capitalization of $28.38B with a current stock price of $188.83.